VYGR · Voyager Therapeutics, Inc.
$3.00
-0.04 (-1.32%)
At close · Jul 29
Market Cap
$181.26M
Shares
60.42M
Voyager Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Voyager Therapeutics, Inc. (VYGR) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲1527.2%
$32.67M
−$12.57M
'19 Q4
20-03-03
▼80%
$6.54M
−$15.93M
'20 Q4
21-02-25
▲329.5%
$28.07M
$5.71M
'21 Q4
22-03-08
▼47.5%
$712,000
−$19.09M
'22 Q2
22-08-04
▲2672.3%
$41.09M
$17.62M
'22 Q3
22-11-08
▼105.5%
$
−$23.63M
'22 Q4
23-03-07
▲22769.3%
$150.48M
$124.04M
'23 Q1
23-05-09
▲581.6%
$4.85M
−$22.21M
'23 Q2
23-08-03
▼88.8%
$4.61M
−$25.90M
'23 Q3
23-11-06
·
$90.06M
$56.40M
'23 Q4
24-02-28
▼87%
$19.52M
−$11.33M
'24 Q1
24-05-13
▲509.5%
$29.58M
−$10.14M
'24 Q2
24-08-06
▲433.8%
$24.63M
−$9.04M
'24 Q3
24-11-12
▼93%
$6.28M
−$34.49M
'24 Q4
25-03-11
▼66.8%
$6.47M
−$31.02M
'25 Q1
25-05-06
LATEST
▼45.7%
$13.37M
−$27.89M
'25 Q3
25-11-10
Earnings call
FY25 · Q3
2025-11-10
Voyager Therapeutics, Inc. Q3 FY2025 Earnings Call
Revenue
$13.37M
▼ 45.7% YoY Diluted EPS
$-0.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Voyager Therapeutics, Inc. Q1 FY2025 Earnings Call
Revenue
$6.47M
▼ 66.8% YoY Diluted EPS
$-0.53
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Voyager Therapeutics, Inc. Q4 FY2024 Earnings Call
Positive tone
Tau programs (antibody and silencing)
External tau data readouts
Gene therapy platform and Zolgensma comparison
Revenue
$6.28M*
▼ 93% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Voyager Therapeutics, Inc. Q3 FY2024 Earnings Call
Positive tone
Anti-tau antibody VY7523 for Alzheimer's disease
Clinical trial plans and timing
Tau silencing gene therapy program
Revenue
$24.63M
▲ 433.8% YoY Diluted EPS
$-0.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Voyager Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone
Tau silencing gene therapy program
Anti-tau antibody VY7523 program
Neurocrine and other partnerships
Revenue
$29.58M
▲ 509.5% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Voyager Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone
VY-TAU01 anti-tau antibody for Alzheimer's
TRACER capsid platform / BBB delivery
Gene therapy pipeline progress (SOD1-ALS, GBA1, FA)
Revenue
$19.52M
▼ 87% YoY Diluted EPS
$-0.20
▼ 106.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Voyager Therapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone
Anti-tau antibody (VY-TAU01) for Alzheimer's
Neurocrine partnership (Friedreich's ataxia)
SOD1 ALS gene therapy
Revenue
$90.06M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Voyager Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$4.61M
▼ 88.8% YoY Diluted EPS
$-0.59
▼ 231.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Voyager Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$4.85M
▲ 581.6% YoY Diluted EPS
$-0.51
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Voyager Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$150.48M
▲ 22769.3% YoY Diluted EPS
$2.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Voyager Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$*
▼ 105.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Voyager Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$41.09M
▲ 2672.3% YoY Diluted EPS
$0.45
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Voyager Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$712,000
▼ 47.5% YoY Diluted EPS
$-0.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Voyager Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$28.07M*
▲ 329.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q4
2021-02-25
Voyager Therapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$6.54M*
▼ 80% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY19 · Q4
2020-03-03
Voyager Therapeutics, Inc. Q4 FY2019 Earnings Call
Revenue
$32.67M
▲ 1527.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–16 of 16 earnings calls
Key facts
CIK
1640266
CUSIP
92915B106
13F (30d)
25 filings
25 filers
Visit website
Investor relations